Hologic (HOLX) director awarded 3,190 restricted stock units of common stock

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Hologic Inc. director Charles J. Dockendorff acquired 3,190 restricted stock units of common stock as a grant. The award was recorded at a price of $0.0000 per share, reflecting a stock-based compensation grant rather than a market purchase.

These restricted stock units vest on the date of Hologic’s 2027 Annual Meeting of Stockholders and are settled in shares of common stock on a one-for-one basis. After this grant, Dockendorff directly holds 6,626 shares of common stock, and indirectly holds 15,370 shares through a revocable trust.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Dockendorff Charles J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	3,190	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 6,626 shares (Direct); Common Stock — 15,370 shares (Indirect, Revocable Trust)

Footnotes (1)

Represents restricted stock units which vest on the date of the 2027 Annual Meeting of Stockholders and are settled in shares of common stock. Restricted stock units are settled in shares of common stock on a one-for-one basis.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/02/2026 - 04:15 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dockendorff Charles J

(Last)

(First)

(Middle)

250 CAMPUS DRIVE

(Street)

MARLBOROUGH

01752

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
HOLOGIC INC [ HOLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/26/2026		A		3,190⁽¹⁾	A	⁽²⁾	6,626	D
Common Stock								15,370	I	Revocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents restricted stock units which vest on the date of the 2027 Annual Meeting of Stockholders and are settled in shares of common stock.

2. Restricted stock units are settled in shares of common stock on a one-for-one basis.

	/s/ Mark W. Irving, attorney-in-fact for Mr. Dockendorff	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Hologic (HOLX) report for Charles J. Dockendorff?

Hologic reported that director Charles J. Dockendorff received a grant of 3,190 restricted stock units of common stock. These units represent stock-based compensation rather than an open-market trade and will convert into shares when they vest.

When do Charles J. Dockendorff’s new Hologic (HOLX) restricted stock units vest?

The 3,190 restricted stock units granted to Charles J. Dockendorff vest on the date of Hologic’s 2027 Annual Meeting of Stockholders. Once vested, they will be settled in shares of common stock on a one-for-one basis.

How many Hologic (HOLX) shares does Charles J. Dockendorff hold after this Form 4?

Following the grant, Charles J. Dockendorff directly holds 6,626 shares of Hologic common stock. In addition, he has indirect ownership of 15,370 shares held through a revocable trust, as disclosed in the filing.

What is the nature of the Hologic (HOLX) equity award granted to Charles J. Dockendorff?

The award consists of 3,190 restricted stock units that will be settled in Hologic common stock on a one-for-one basis. These units vest on the date of the company’s 2027 Annual Meeting of Stockholders, aligning the director’s interests with shareholders.

Did Charles J. Dockendorff buy or sell Hologic (HOLX) shares on the market in this Form 4?

No open-market buy or sell was reported. The Form 4 shows an acquisition coded as a grant of 3,190 restricted stock units at a stated price of $0.0000 per share, indicating a compensation-related award rather than a market transaction.

How are Charles J. Dockendorff’s indirect Hologic (HOLX) holdings structured?

The Form 4 discloses 15,370 Hologic common shares held indirectly by Charles J. Dockendorff through a revocable trust. This is classified as indirect ownership, separate from his 6,626 directly held shares after the reported grant.